Cormorant Asset Management as of Sept. 30, 2016
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 84 positions in its portfolio as reported in the September 2016 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Alder Biopharmaceuticals | 6.1 | $55M | 1.7M | 32.77 | |
Nevro (NVRO) | 5.7 | $51M | 491k | 104.39 | |
Theravance Biopharma (TBPH) | 4.5 | $41M | 1.1M | 36.24 | |
Minerva Neurosciences | 4.4 | $40M | 2.8M | 14.12 | |
Proteostasis Therapeutics In | 4.0 | $37M | 2.4M | 15.59 | |
Clearside Biomedical (CLSD) | 3.8 | $35M | 2.0M | 17.35 | |
Eagle Pharmaceuticals (EGRX) | 3.5 | $32M | 456k | 70.00 | |
Heron Therapeutics (HRTX) | 3.4 | $31M | 1.8M | 17.23 | |
Ardelyx (ARDX) | 3.0 | $27M | 2.1M | 12.94 | |
Myokardia | 2.9 | $26M | 1.6M | 16.34 | |
Clovis Oncology | 2.6 | $23M | 650k | 36.05 | |
Aclaris Therapeutics (ACRS) | 2.5 | $23M | 901k | 25.61 | |
Quotient | 2.4 | $22M | 2.8M | 7.82 | |
Galapagos Nv- (GLPG) | 2.4 | $21M | 334k | 64.19 | |
Macrogenics (MGNX) | 2.3 | $21M | 708k | 29.91 | |
Neurocrine Biosciences (NBIX) | 2.2 | $20M | 398k | 50.64 | |
Omeros Corporation (OMER) | 2.1 | $19M | 1.7M | 11.16 | |
Protagonist Therapeutics (PTGX) | 1.9 | $17M | 800k | 21.13 | |
Wave Life Sciences (WVE) | 1.8 | $17M | 508k | 32.47 | |
Sorrento Therapeutics (SRNE) | 1.8 | $16M | 2.1M | 7.74 | |
Coherus Biosciences (CHRS) | 1.7 | $15M | 576k | 26.78 | |
China Biologic Products | 1.6 | $14M | 113k | 124.48 | |
Corbus Pharmaceuticals Hldgs | 1.5 | $14M | 2.0M | 6.79 | |
Portola Pharmaceuticals | 1.5 | $14M | 596k | 22.71 | |
Cellectis S A (CLLS) | 1.3 | $12M | 498k | 24.08 | |
Agenus | 1.2 | $11M | 1.6M | 7.18 | |
Invuity | 1.2 | $11M | 768k | 13.72 | |
Advaxis | 1.1 | $9.8M | 921k | 10.69 | |
Gemphire Therapeutics | 1.1 | $9.8M | 900k | 10.92 | |
Contrafect | 1.1 | $9.5M | 3.8M | 2.48 | |
Inc Resh Hldgs Inc cl a | 1.0 | $8.9M | 200k | 44.58 | |
Blueprint Medicines (BPMC) | 1.0 | $8.9M | 299k | 29.70 | |
Dex (DXCM) | 1.0 | $8.8M | 100k | 87.66 | |
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 1.0 | $8.8M | 456k | 19.26 | |
Alnylam Pharmaceuticals (ALNY) | 0.9 | $8.5M | 126k | 67.78 | |
Achillion Pharmaceuticals | 0.9 | $8.1M | 1.0M | 8.10 | |
Audentes Therapeutics | 0.9 | $8.0M | 450k | 17.81 | |
Emergent BioSolutions (EBS) | 0.9 | $7.9M | 250k | 31.53 | |
Ultragenyx Pharmaceutical (RARE) | 0.9 | $7.9M | 111k | 70.94 | |
Array BioPharma | 0.9 | $7.8M | 1.2M | 6.75 | |
Fulgent Genetics (FLGT) | 0.8 | $7.4M | 800k | 9.22 | |
Forward Pharma A/s | 0.8 | $7.1M | 339k | 21.00 | |
Sangamo Biosciences (SGMO) | 0.7 | $6.5M | 1.4M | 4.63 | |
Curis | 0.7 | $6.3M | 2.4M | 2.61 | |
Zynerba Pharmaceuticals | 0.7 | $6.3M | 481k | 13.05 | |
Recro Pharma | 0.7 | $5.9M | 669k | 8.84 | |
Dermira | 0.6 | $5.8M | 172k | 33.82 | |
Cytomx Therapeutics (CTMX) | 0.6 | $5.8M | 372k | 15.68 | |
Pfenex | 0.6 | $5.7M | 633k | 8.95 | |
Avexis | 0.6 | $5.4M | 132k | 41.21 | |
Catabasis Pharmaceuticals | 0.5 | $4.9M | 800k | 6.16 | |
Intec Pharma | 0.5 | $4.8M | 810k | 5.88 | |
Acceleron Pharma | 0.5 | $4.6M | 128k | 36.19 | |
Oncobiologics | 0.5 | $4.4M | 1.0M | 4.25 | |
Rigel Pharmaceuticals | 0.5 | $4.2M | 1.2M | 3.67 | |
Lion Biotechnologies | 0.5 | $4.2M | 506k | 8.23 | |
Atara Biotherapeutics | 0.4 | $4.0M | 187k | 21.39 | |
Agile Therapeutics | 0.4 | $3.9M | 564k | 6.98 | |
Syndax Pharmaceuticals (SNDX) | 0.4 | $3.6M | 240k | 15.16 | |
Corvus Pharmaceuticals (CRVS) | 0.4 | $3.5M | 214k | 16.45 | |
Lipocine | 0.4 | $3.4M | 751k | 4.46 | |
Immune Design | 0.4 | $3.3M | 433k | 7.58 | |
Aptose Biosciences | 0.2 | $2.2M | 991k | 2.25 | |
Regenxbio Inc equity us cm (RGNX) | 0.2 | $2.2M | 157k | 14.01 | |
Glycomimetics (GLYC) | 0.2 | $2.1M | 287k | 7.15 | |
Aquinox Pharmaceuticals | 0.2 | $2.0M | 152k | 13.36 | |
Celyad Sa | 0.2 | $1.8M | 76k | 23.59 | |
Epizyme | 0.2 | $1.6M | 160k | 9.84 | |
Ascendis Pharma A S (ASND) | 0.1 | $1.3M | 62k | 20.10 | |
Amicus Therapeutics (FOLD) | 0.1 | $1.1M | 152k | 7.40 | |
AVEO Pharmaceuticals | 0.1 | $968k | 1.1M | 0.89 | |
Nanostring Technologies (NSTGQ) | 0.1 | $809k | 41k | 19.98 | |
Threshold Pharmaceuticals | 0.1 | $688k | 1.0M | 0.68 | |
Oncobiologics Inc *w exp 05/18/201 | 0.1 | $500k | 417k | 1.20 | |
Genvec | 0.1 | $467k | 1.0M | 0.46 | |
Htg Molecular Diagnostics | 0.1 | $472k | 204k | 2.32 | |
Neos Therapeutics | 0.0 | $333k | 51k | 6.58 | |
Provectus Biopharmaceuticals I (PVCT) | 0.0 | $223k | 2.2M | 0.10 | |
Applied Genetic Technol Corp C | 0.0 | $169k | 17k | 9.76 | |
Adaptimmune Therapeutics (ADAP) | 0.0 | $178k | 25k | 7.03 | |
Cellectar Biosciences | 0.0 | $145k | 54k | 2.70 | |
Oncobiologics Inc *w exp 02/18/201 | 0.0 | $200k | 417k | 0.48 | |
Provectus Biopharmaceuticals *w exp 06/24/202 | 0.0 | $110k | 2.2M | 0.05 | |
Cellectar Biosciences Equity Warrants *w | 0.0 | $13k | 53k | 0.25 |